Shionogi Announces Publication of Two Studies in the Lancet Infectious Diseases Highlighting the Efficacy and Safety of Cefiderocol for the Treatment of Infections Due to Aerobic Gram-negative Bacteria in Adults With Limited Treatment Options
13.10.2020 10:00:00 EEST | Business Wire | Press release
FOR MEDICAL AND PHARMA TRADE MEDIA ONLY
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President & CEO: Isao Teshirogi, Ph.D.) (hereafter "Shionogi") today announces the back to back publication of two studies in The Lancet Infectious Diseases journal highlighting the efficacy and safety of cefiderocol against some of the most difficult-to-treat Gram-negative bacterial infections, including nosocomial pneumonia (NP), bloodstream infections (BSI), sepsis, and complicated urinary tract infections (cUTI).1,2
APEKS-NP was a Phase 3 clinical trial designed to compare the efficacy and safety of cefiderocol versus high-dose, extended-infusion meropenem (2g, q8h, 3-hour infusion) in critically ill patients with hospital-acquired, ventilator-associated, or healthcare-associated pneumonia (HAP, VAP, and HCAP, respectively) caused by a broad range of Gram-negative bacteria, like Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacterales, including patients at risk of MDR infections. The study successfully met the primary endpoint of non-inferiority in all-cause mortality (ACM) at Day 14 with 12.4% for the cefiderocol arm (18/145) and 11.6% for the meropenem arm (17/146; adjusted treatment difference 0.8% [95% CI –6.6 to 8.2]) in the modified intention-to treat-population (mITT population). Cefiderocol was well tolerated, and its safety profile was consistent with that of other cephalosporins and/or carbapenems.1
The CREDIBLE-CR trial was a small non-inferential Phase 3 open label, pathogen-focused trial designed to assess the efficacy and safety of cefiderocol or best available therapy (BAT) for the treatment of a diverse range of serious CR infections including CR non-fermenters and carbapenemase producers consisting of NP, BSI, sepsis, and cUTI. BAT was combination therapy in 71% (27/38) of cases with 28 different BAT regimens being used, whereas 83% (66/80) of cefiderocol treatment was monotherapy. Two thirds (66% [25/38]) of the BAT regimens contained colistin.2
The results of the CREDIBLE-CR study provided descriptive evidence of the efficacy and safety of cefiderocol in CR Gram-negative infections in a highly heterogeneous patient population frequently presenting with complex comorbidities. The clinical and microbiological outcomes were generally similar between cefiderocol and BAT, except for metallo-beta-lactamases infections where cefiderocol was substantially better (cefiderocol: 75% and 44%; BAT: 29% and 14%, respectively). There was an observed mortality difference between treatment arms in the subset of patients with Acinetobacter spp. infections, likely linked to imbalances in risk factors at baseline. There was no mortality difference observed in P. aeruginosa or Enterobacterales without Acinetobacter spp. co-infection. No deaths were attributed to cefiderocol-related adverse events as examined by investigators assessing the mortality imbalance.2
“The patient population in the CREDIBLE-CR study represents a real clinical scenario with the highest unmet need and provides descriptive evidence that cefiderocol may be a treatment option for physicians treating such critically ill patients,” commented Professor Matteo Bassetti, Lead Author and Head of the Infectious Diseases Clinic, San Martino Hospital, Genoa, Italy.
“From the results of APEKS-NP and CREDIBLE-CR studies, we believe that cefiderocol becomes a new option for the treatment of patients at risk of multi-drug resistant Gram-negative infections”, said Takuko Sawada, Director and Executive Vice President, Senior Vice President of Integrated Disease Care Department of Shionogi.
Cefiderocol received European Commission (EC) marketing authorisation for the treatment of infections due to aerobic Gram-negative bacteria in adults with limited treatment options under the brand name FETCROJA® in April 2020 and is now commercially available in the UK. Shionogi remains committed to making the drug available further in Europe as quickly as possible.6
Cefiderocol is the first treatment which provides coverage against all Gram-negative pathogens considered of critical priority by the WHO – carbapenem -resistant A. baumannii, P. aeruginosa, and Enterobacterales.3,4
Antimicrobial resistance (AMR)
Antimicrobial resistance (AMR) is a major health burden which urgently needs to be addressed. Globally, approximately 700,000 people die as a result of infections caused by resistant pathogens every year. Infections caused by carbapenem-resistant Gram-negative bacteria are often associated with a high mortality rate.7 If no action is taken, antibiotic resistance is predicted to kill 10 million people every year by 2050, at a cumulative cost to global economic output of 100 trillion USD.5
About FETCROJA® (cefiderocol)
Cefiderocol is a cephalosporin antibiotic with a novel mechanism for penetrating the outer cell membrane of Gram-negative pathogens by acting as a siderophore. In addition to entering cells by passive diffusion through porin channels, cefiderocol binds to ferric iron and is actively transported into bacterial cells through the outer membrane via the bacterial iron transporters, which function to incorporate this essential nutrient for bacteria.8 These mechanisms allow cefiderocol to achieve higher concentrations in the periplasmic space where it can bind to penicillin-binding proteins and inhibit cell wall synthesis in the bacterial cells.9 Cefiderocol has also demonstrated in vitro activity against certain bacteria that contain very problematic resistant enzymes such as ESBLs, AmpC, serine- and metallo-carbapenemases.10,11 Data from multinational surveillance studies for cefiderocol demonstrated potent in vitro activity against a wide spectrum of Gram-negative pathogens including carbapenem-resistant A. baumannii, P. aeruginosa, Enterobacterales, and Stenotrophomonas maltophilia.12 The clinical significance of the in vitro data is unknown. Cefiderocol has no clinically relevant activity against Gram-positive or anaerobic bacteria.
Cefiderocol is commercially available in the U.S after approval by the FDA in 2019 under the brand name FETROJA® for patients 18 years of age or older who have limited or no alternative treatment options, for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by the following: susceptible Gram-negative microorganisms: E. coli, K. pneumoniae, P. mirabilis, P. aeruginosa, and E. cloacae complex.13
Shionogi’s commitment to fighting antimicrobial resistance
Shionogi has a strong heritage in the field of anti-infectives and has been developing antimicrobial therapies for more than 60 years. Shionogi is proud to be one of the few large pharmaceutical companies that continues to focus on research and development in anti-infectives. The company invests the highest proportion of its pharmaceutical revenues in relevant anti-infectives R&D compared to other large pharmaceutical companies.14
For more information please refer to: https://www.shionogi.com/global/en/sustainability/amr.html
About Shionogi
Shionogi & Co., Ltd. is a 142-year-old global, research driven pharmaceutical company headquartered in Osaka, Japan, that is dedicated to bringing benefits to patients based on its corporate philosophy of “supplying the best possible medicine to protect the health and wellbeing of the patients we serve.” The company currently markets products in several therapeutic areas including anti-infectives, pain, CNS disorders, cardiovascular diseases and gastroenterology. Shionogi’s research and development currently target two therapeutic areas: infectious diseases, and pain/CNS disorders.
For more information on Shionogi & Co., Ltd., please visit https://www.shionogi.com/global/en/
Shionogi B.V. is the European headquarters of Shionogi & Co., Ltd. For more information on Shionogi B.V., please visit www.shionogi.eu.
Forward Looking Statement
This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also, for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
© 2020 Shionogi Europe. London, WC2B 6UF. All Rights Reserved.
References
1 Wunderrink RG et al, Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a Phase 3, randomised, double-blind, non-inferiority study, The Lancet Infectious Diseases 2020. Available at: https://doi.org/10.1016/S1473-3099(20)30731-3. Last accessed October 2020
2 Bassetti M, Efficacy and safety of cefiderocol for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): results of a Phase 3 randomised, open-label, parallel-assigned, pathogen-focused study, The Lancet Infectious Diseases 2020. Available at: https://doi.org/10.1016/S1473-3099(20)30796-9. Last accessed October 2020
3 World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. February 27, 2017. Retrieved from https://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en/. Last accessed July 2020
4 World Health Organization. 2019 Antibacterial Agents in Clinical Development. 2019. Retrieved from
https://apps.who.int/iris/bitstream/handle/10665/330420/9789240000193-eng.pdf Last accessed July 2020
5 O’Neill, J. et al. Review on antimicrobial resistance. Tackling drug-resistant infections globally: final report and recommendations. 2016 https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf Last accessed July 2020
6 https://www.ema.europa.eu/en/medicines/human/EPAR/fetcroja
7 Perez F, et al. ‘Carbapenem-Resistant Enterobacteriaceae: A Menace to our Most Vulnerable Patients’. Cleve Clin J Med. Apr 2013; 80(4): 225–33
8 Ito A, Nishikawa T., Masumoto S, et al. Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2016;60(12):7396-7401
9 Tillotson GS. Trojan Horse Antibiotics—A Novel Way to Circumvent Gram-Negative Bacterial Resistance? Infectious Diseases: Research and Treatment. 2016;9:45-52 doi:10.4137/IDRT.S3156
10 K Kazmierczak et al. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study). ). International Journal of Antimicrobial Agents, 2019; 53(2) 177-184
11 A Ito et al. In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria. Antimicrobial Agents and Chemotherapy, 2018, 62:e01454-17.
12 M Hackel, M Tsuji, Y Yamano, et al. In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, Against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem Non-Susceptible Isolates: The SIDERO-WT-2014 Study. Antimicrobial Agents Chemotherapy. 2017;61(9)
13 FETROJA (cefiderocol) prescribing information. Florham Park, N.J. Shionogi Inc.: November 2019
14 Antimicrobial Resistance Benchmark 2020.
https://accesstomedicinefoundation.org/media/uploads/downloads/5e270aa36821a_Antimicrobial_Resistance_Benchmark_2020 pdf Last accessed July 2020
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201013005303/en/
Contact information
For further information, contact:
Shionogi & Co., Ltd.
Corporate Communications
Telephone: +81-6-6209-7885
Fax: +81-6-6229-9596
Shionogi Europe Media Contact
Dr. Mark Hill, Shionogi
mark.hill@shionogi.eu
Havas SO Media Contact
Nicola Lilley
Senior Account Director
+44 (0)20 3196 9912
Nicola.lilley@havasso.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP and Formula 1 Partner to Reveal the Human Performance Behind the Wheel18.11.2026 19:00:00 EET | Press release
WHOOP, the human performance brand, today announced a four-year global partnership with Formula 1, becoming the Official Health & Fitness Wearable Partner of Formula 1 and the first consumer wearable approved by the FIA for in-race use. Beginning in 2027, the partnership will bring continuous physiological monitoring to one of the world's most demanding sports, helping drivers and teams better understand how their bodies respond to the demands of competition while giving fans a new perspective on the human performance behind the wheel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118567291/en/ WHOOP and Formula 1 Partner to Reveal the Human Performance Behind the Wheel WHOOP is working to bring fans closer to the action than ever before, with Formula 1 integrating real-time physiological data from participating drivers into its broadcast across the season through WHOOP Live. For the first time, fans will be able to see
Xsolla Connects Players, Brands, and Video Game Audiences Through Rewarded Engagement18.11.2026 17:16:00 EET | Press release
Xsolla (USA), Inc., a global commerce company, announces Xsolla Ads, a rewarded marketing solution connecting brands with game audiences through quests players choose to take part in. Studios generate revenue beyond player purchases while brands drive measurable engagement, acquisition, and purchases. Players choose which campaigns to participate in and which rewards to receive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117947414/en/ Graphic: Xsolla Players see Xsolla Ads where they already are, including the Xsolla App, game web shops, branded pages on Xsolla, Xsolla Choice surveys, and an opt-in Offerwall. Quests are triggered by game events, such as reaching a new level or season, so studios connect campaigns to what players already do in their games. Completed quests can unlock in-game currency, digital items, Xsolla Points, and other rewards delivered through Xsolla Backpack, where players store their digital it
Future Health Launches Academy to Translate Life Sciences Advances Into Strategic Action18.11.2026 16:37:00 EET | Press release
Future Health - A Global Initiative by Abu Dhabi has launched the Future Health Academy as part of its year-round programme, designed to build knowledge, connect expertise and create opportunities for collaboration among health and life sciences professionals in Abu Dhabi and internationally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118051527/en/ The Future Health Academy will build knowledge and connect expertise among health and life sciences professionals in Abu Dhabi and internationally. Through practical, science-focused learning, the Academy will create opportunities for local and international professionals across the health and life sciences ecosystem to engage with emerging developments and consider their implications for research, clinical practice, investment and innovation. Drawing on leading local and international expertise, it will support two-way knowledge exchange by bringing global perspectives to
Soracom Launches Physical AI Suite, Bringing Secure Connectivity and Remote Operations to Robots and Autonomous Machines18.11.2026 16:30:00 EET | Press release
Soracom, Inc. (TSE: 147A), a cloud-native IoT platform providing connectivity, cloud integration, and AI services for the Internet of Things, today announced Soracom Physical AI Suite, a set of Soracom platform services combined to connect, protect, and manage physical AI systems such as robots, autonomous mobile machines, and industrial equipment. Soracom Physical AI Suite is the company's second suite, following Soracom Automotive Suite announced in July 2026. Each suite brings together Soracom platform services commonly used for a particular type of deployment, organizing them into a single system. A team starting a new deployment begins from that system instead of selecting and assembling services one at a time. The suite is designed for companies that develop or deploy robots and other physical AI systems and for companies that operate connected equipment in industries including manufacturing, logistics, energy, infrastructure, and building management. A physical AI system extends
Variational Raises $110M Series B at $1.5B Valuation To Scale On-Chain Access To Global Markets18.11.2026 16:23:00 EET | Press release
Variational, a protocol for on-chain derivatives trading, has announced a $110M Series B raise at a $1.5B valuation led by Bain Capital Crypto with support from Dragonfly, HSG, Peak XV, 50T Funds, and more. Since launching in early 2025, the platform has processed $475B+ in trading volume and accumulated $1.3B+ in open interest across 100k+ accounts. More than half of daily volume on the platform is now on traditional markets. The raise will fund the platform’s continued growth, allowing Variational to list hundreds more markets and lift open interest caps that traders increasingly hit. Omni, a trading platform built on Variational, offers leveraged trading on 550+ crypto and traditional markets. Unlike other on-chain trading platforms, Omni aggregates liquidity from both traditional and on-chain markets. This model allowed the platform to launch “swaps” in September 2026, a new instrument that gives on-chain traders access to liquidity from traditional financial institutions. Swaps ar
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
